Literature DB >> 8898755

A model of measles virus-induced immunosuppression: enhanced susceptibility of neonatal human PBLs.

A Tishon1, M Manchester, F Scheiflinger, M B Oldstone.   

Abstract

Measles virus (MV) still incites one of the most contagious infections of humankind. Despite the development and use of an excellent live attenuated virus vaccine, over one million infants and children continue to die each year from measles. The main cause of morbidity and mortality is virus-induced immunosuppression of lymphocyte function, which allows secondary infections. Here we report an in vivo model for the study of MV-induced immunosuppression. Human peripheral blood leukocytes (PBLs) grafted onto mice with severe combined immunodeficiency disease (SCID mice) to create hu-PBLS-SCID mice produce human IgG that is suppressed by MV infection. Immunosuppression is dependent on the involvement of live virus and is dramatically more severe for PBLs obtained from newborns than PBLs from adults. Suppression of IgG synthesis by PBLs from newborns occurs as early as ten days after administration of MV to hu-PBLS-SCID mice compared with 44 days required for PBLs from adults. Further, MV infection of SCID mice reconstituted with PBLs from newborns.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898755     DOI: 10.1038/nm1196-1250

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  10 in total

Review 1.  Negative signaling in health and disease.

Authors:  K M Coggeshall
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Inhibition of in vitro leukocyte proliferation by morbilliviruses.

Authors:  J Heaney; T Barrett; S L Cosby
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Measles virus-induced immune suppression in the cotton rat (Sigmodon hispidus) model depends on viral glycoproteins.

Authors:  S Niewiesk; I Eisenhuth; A Fooks; J C Clegg; J J Schnorr; S Schneider-Schaulies; V ter Meulen
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Malaria infection induces rapid elevation of the soluble Fas ligand level in serum and subsequent T lymphocytopenia: possible factors responsible for the differences in susceptibility of two species of Macaca monkeys to Plasmodium coatneyi infection.

Authors:  J Matsumoto; S Kawai; K Terao; M Kirinoki; Y Yasutomi; M Aikawa; H Matsuda
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

5.  Selective in vivo suppression of T lymphocyte responses in experimental measles virus infection.

Authors:  S Niewiesk; M Götzelmann; V ter Meulen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

6.  The effects of pharmacological and lentivirus-induced immune suppression on orbivirus pathogenesis: assessment of virus burden in blood monocytes and tissues by reverse transcription-in situ PCR.

Authors:  S J Brodie; W C Wilson; P M O'Hearn; D Muthui; K Diem; L D Pearson
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

7.  Measles virus infection induces terminal differentiation of human thymic epithelial cells.

Authors:  H Valentin; O Azocar; B Horvat; R Williems; R Garrone; A Evlashev; M L Toribio; C Rabourdin-Combe
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Measles virus nucleocapsid protein binds to FcgammaRII and inhibits human B cell antibody production.

Authors:  K Ravanel; C Castelle; T Defrance; T F Wild; D Charron; V Lotteau; C Rabourdin-Combe
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

9.  Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients.

Authors:  Karen Yao; Susan Gagnon; Nahid Akhyani; Elizabeth Williams; Julie Fotheringham; Elliot Frohman; Olaf Stuve; Nancy Monson; Michael K Racke; Steven Jacobson
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

10.  Down-regulation of CD46 by piliated Neisseria gonorrhoeae.

Authors:  Darcy B Gill; Michael Koomey; Janne G Cannon; John P Atkinson
Journal:  J Exp Med       Date:  2003-11-03       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.